Inhibition of platelet monoamine oxidase type B by selegiline

Journal of Clinical Pharmacology

Volumn 37, Issue 7, 1997, Pages 597-601

  Heinonen, Esa H ^a,b   Anttila, Markku I ^a   Nyman, Leena M ^a   Pyykkö, Kaija A ^a   Vuorinen, Jouni A ^a   Lammintausta, Risto A S ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b ORION CORPORATION   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); MONOAMINE OXIDASE INHIBITOR; SELEGILINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BIOAVAILABILITY; ENZYME INHIBITION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL;

EID: 0030796219     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04341.x     Document Type: Article

References (15)

1. Tetrud JW, Langston JW: The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245:519-522.
2. The Parkinson Study Group: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328:176-183.
3. Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH: Selegiline as initial treatment in de novo parkinsonian patients. Neurology 1992; 42:339-343.
4. Heinonen EH, Rinne UK: Selegiline in the treatment of Parkinson's disease. Acta Neurol Scand 1989; 80:103-111.
5. Heinonen EH, Lammintausta R: A review of the pharmacology of selegiline. Acta Neurol Scand 1991; 84:44-59.
6. Salo PT, Tatton WG: Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 1992; 31:394-400.
7. Heinonen EH, Anttila M, Karnani H, Lammintausta R: Pharmacokinetics of selegiline after oral dosing. Mov Disord 1994; 9(suppl 1):P248.
8. Da Prada M, Cesura AM, Launay JM, Richards JG: Platelets as a model for neurons? Experiment 1988; 44(2):115-126.
9. Birkmayer W, Riederer P, Ambrozi L, Youdim MBH: Implications of combined treatment with 'Madopar' and L-deprenyl in Parkinson's disease. Lancet 1977; 1:439-443.
10. Lees AJ, Kohout LJ, Shaw KM, Stern GM, Elseworth JD, Sandler M, Youdim MBH: Deprenyl in Parkinson's disease. Lancet 1977; ii:791-795.
11. Wajsbort J, Kartmazov K, Oppenheim B, Barkey R, Youdim MBH: The clinical and biochemical investigation of L-deprenyl in Parkinson's disease with special reference to the "on-off" effect. J Neural Transm 1982; 55:201-215.
12. Koulu M, Scheinin M, Kaarttinen A, Kallio J, Pyykkö K, Vuorinen J, Zimmer RH: Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Clin Pharmacol 1989; 27:243-255.
13. Little JE, Milliken GA, Schwenke JR: The analysis of William Square designs with several subjects per sequence. In, Proceedings of the Biopharmaceutical Section. New Orleans, American Statistical Association, 1988; 232-234.
14. Heinonen EH, Anttila MI, Karnani HL, Nyman LM, Vuorinen JA, Pyykkö KA, Lammintausta RAS: Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of MAO-B in human subjects. J Clin Pharmacol 1997; 37:602-609.
15. Heinonen EH, Anttila MI, Lammintausta RAS: Pharmacokinetics and clinical pharmacology of selegiline: In, Szelenyi I (ed.): Inhibitors of Monoamine Oxidase B. Basel: Birkhäuser Verlag AG, 1992; 201-213.